I did not say--Goldman Sachs is slow.GS is very creative-look at Amylin buyout. BMY was sticking with 27-28$ price(from press leakage),GS convinced Astra Zeneca to join in the Joint bid and then got 31$/share that satisfied Amylin.This set of events were reported(leaked every week--another funny but interesting way to push prices higher to close Bid-Ask gap.
As far as Pfizer-- my conclusion is based on fact that Pfizer sales in Cardiology field are dropping lsharply inspite of their several measures.Also,they learnt in 1996-99 from Warner Lambert that if they wait for the sales performance or Reduce-IT study--they may have to pay far more. Pfizer is marketing anything they can find. Nexium OTC business from 2014--Astra Zeneca gave them rights for 250 mil.$ plus royalties payment to AZN. Pfizer pipeline is empty.
Merck--is not smart-missed Lipitor in 1996; missed Pharmaccett (Hep.C drug) in 2010 or 2011. Their top management is hesitant and hostage to NOT INVENTED HERE.
As far as price is concerned--15$ was offered in April-May,2011 (most probably Pfizer).With Anchor trial results plus patents--22$/share is the price low in the range.They know start bid at 22$--and then move it to 28$ for final bid. Normal process.
GSK--will wait for Sales performance--before they invest3 or 4 bil.$ in Amarin.